Journal Article

Efficacy and safety of moxidectin compared with ivermectin against Strongyloides stercoralis infection in adults in Laos and Cambodia: a randomised, double-blind, non-inferiority, phase 2b/3 trial

Hofmann, Daniela, Sprecher, Viviane P, Sayasone, Somphou, Hattendorf, Jan, Keiser, Jennifer, Savathdy, Vanthanom, Xayavong, Phengsavanh, Huy, Rekol, Norkhankhame, Chomseng, Khieu, Virak

2024

Overview

Infection with the soil-transmitted helminth Strongyloides stercoralis affects up to 600 million people globally, most of whom live in rural areas with poor sanitation. If untreated, infection leads to long-lasting morbidity and might even be life-threatening. Moxidectin might be a promising alternative to ivermectin, the only currently recommended single-dose treatment. We aimed to assess whether moxidectin is non-inferior in terms of efficacy and safety compared with ivermectin. In this randomised, double-blind, parallel-group, non-inferiority, phase 2b/3 trial in communities in Laos and Cambodia, adults aged 18–65 years were screened for the presence of S stercoralis larvae in their stool via sextuplicate quantitative Baermann assays. Using computer-generated group allocation (block randomisation stratified by infection intensity), parasitologically (two or more positive Baermann assays) and clinically eligible participants were randomly assigned (1:1) to receive single oral doses of either moxidectin (8 mg) and ivermectin-matched placebo, or ivermectin (200 μg/kg bodyweight) and moxidectin-matched placebo. The primary endpoint was cure rate assessed at 14–21 days after treatment, using the available-case population analysed according to intention-to-treat principles. Moxidectin was considered non-inferior to ivermectin if the lower limit of the two-sided 95% CI of the difference was greater than the non-inferiority margin of –10 percentage points. Safety endpoints were assessed before treatment, and at 2–3 h, 24 h, and 14–21 days after treatment. This trial is registered at ClinicalTrials.gov, NCT04056325 and NCT04848688. Between Dec 6, 2020, and May 21, 2022, 4291 participants were screened, 726 of whom were enrolled and randomly assigned to moxidectin (n=363) or ivermectin (n=363). For the participants with primary outcome data, we observed a cure rate of 93·6% (95% CI 90·5 to 96·0; 324 of 346 participants) in the moxidectin group and 95·7% (93·0 to 97·6; 335 of 350 participants) in the ivermectin group, resulting in a between-group difference of –2·1 percentage points (95% CI –5·5 to 1·3). The most common adverse events were abdominal pain (32 [9%] of 363 with moxidectin vs 34 [9%] of 363 with ivermectin) and headache (25 [7%] vs 30 [8%]), which were predominantly mild and transient. Moxidectin was non-inferior to ivermectin in terms of efficacy in the treatment of strongyloidiasis. Additionally, both drugs had a similar safety profile. The fixed dose and lower cost of moxidectin compared with ivermectin make it a valuable alternative for people with strongyloidiasis. Swiss National Science Foundation.

• Publisher: Elsevier Ltd,Elsevier Limited
• Subject: Adult / Adults / Animals / Cambodia - epidemiology / Chemotherapy / Community / Disease prevention / Double-Blind Method / Drug dosages / Effectiveness / Ethics / Headache / Humans / Infections / Ivermectin / Ivermectin - adverse effects / Laos / Larvae / Macrolides / Medical research / Morbidity / Mortality / Parasitic diseases / Placebos / Quality control / Randomization / Rural areas / Safety / Sanitation / Strongyloides stercoralis / Strongyloidiasis / Strongyloidiasis - drug therapy / Treatment Outcome / Tropical diseases / Veterinary medicine / Viral infections